Follow The Filings

PYXS Pyxis Oncology

Pyxis Oncology earnings company data as of 8:01 PM ET 10/22

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

2 periods, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 2 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by PYXS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PYXS insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $107K sold by 1 insider under 10b5-1 plans
  1. GordonMD Global Investments LP 10% owner, +3 joint filers
    Buy
    — 5,517,000 shares +55% to stake
    Traded Oct 1 Filed Oct 2
  2. Jakob Dupont Director
    Planned sale
    $107K 35,000 shares at $3.06 48% of stake
    Traded Jun 30 Filed Jul 2
  3. Rachel Humphrey Director
    Planned sale
    $16K 15,496 shares at $1.03 16% of stake
    Traded Apr 14–21 Filed Mar 25

Also filed in the last 12 months, not counted as buying or selling: 1 stock grant and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
DEF 14A
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 1.01,8.01,9.01
424B5 FORM 424B5
424B5 FORM 424B5
424B5 FORM 424B5
8-K 7.01,8.01,9.01
8-K 5.02,7.01,9.01
424B2
8-K 2.02
10-Q
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 1.01,3.02,7.01
8-K 5.07
8-K 2.02
10-Q
DEF 14A
8-K/A 5.02
DEFA14A
8-K 2.02,7.01
10-K
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.